dr. weber on discontinuing immunotherapy in melanoma
Published 6 years ago • 1.4K plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
1:16
dr. weber on emerging immunotherapy combinations in melanoma
-
1:03
dr. weber on risk and benefits with immunotherapy combos in melanoma
-
1:46
dr. weber on selecting immunotherapy for patients with melanoma
-
2:06
dr. weber on next steps with pembrolizumab as melanoma treatment
-
0:49
dr. weber on emerging therapies in melanoma
-
0:57
dr. weber on fda approval of pembrolizumab for stage iii melanoma
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
1:08
dr. weber discusses toxicity of immunotherapies in melanoma
-
7:00
metastatic melanoma: the immunotherapy approach
-
2:05
dr. weber on adjuvant approaches in stage iii melanoma
-
1:58
dr. weber on duration of checkpoint inhibitor therapy in melanoma
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
1:29
dr. weber on future treatment approaches for patients with melanoma
-
1:14
dr. weber discusses advancements in melanoma
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
8:35
long-term results for immunotherapy in melanoma
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma